soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study Oral Semaglutide Reduces Cardiovascular Events

Yes, tirzepatide should be discontinued when pregnancy is recognized or before planned conception

The 9-month interval for maintenance patients acknowledges that once you reach a stable dose with consistent results, frequent provider visits add less value

Market Concentration & Characteristics The semaglutide market is evolving with advancements in drug formulations, delivery systems, and combination therapies

combines GLP-1 and GIP receptor activity and shows strong weight loss effects

For example, an increasing number of patients have reported constant vomiting, diarrhea, pancreatitis, gastroparesis and host of other life-altering side effects